FDA Approval Alert: The Need-to-Know | Adagrasib for KRAS G12C–Mutated NSCLC

In December 2022, adagrasib was granted accelerated approval by the FDA for patients with KRAS G12C–mutated non–small cell lung cancer, as determined by an FDA-approved test.

Alexander Spira, MD, PhD, FACP, of the Virginia Cancer Specialists, discusses how the FDA approval of adagrasib for KRAS G12C–mutated non–small cell lung cancer can provide benefit for this patient population.
Approval of Adagrasib for KRAS G12C–Mutated NSCLC Will ‘Open Up Another Therapeutic Option’, Says Expert
Video
Dec 14, 2022 3:00 PM
Alexander Spira, MD, PhD, FACP, of the Virginia Cancer Specialists, discusses how the FDA approval of adagrasib for KRAS G12C–mutated non–small cell lung cancer can provide benefit for this patient population.
FDA Grants Accelerated Approval to Adagrasib for KRAS G12C–Mutated NSCLC
FDA Grants Accelerated Approval to Adagrasib for KRAS G12C–Mutated NSCLC
Article
Dec 13, 2022 3:28 PM
Patients with KRAS G12C–mutated non–small cell lung cancer can now receive adagrasib therapy following the treatment’s recent accelerated approval by the FDA.